Radiation and immunotherapy combo tested for stubborn lymphoma

NCT ID NCT04827862

Summary

This study is testing whether adding low-dose radiation to an immunotherapy drug (pembrolizumab) can help control non-Hodgkin lymphoma that has come back or stopped responding to other treatments. It is for adults whose cancer has progressed after at least two prior therapies. The goal is to see if this combination can shrink tumors and keep the disease under control for longer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Abamson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.